BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...many venture investors to walk away from the space (see “Money Troubles”). One exception is Cytox Ltd....
...The assay screens for 130,000 SNPs, including about 30,000 associated with mTOR signaling in AD. Cytox...
...are correlated with amyloid deposition and other pathways implicated in AD in genome-wide association studies. Cytox...
BioCentury | Aug 8, 2016
Company News

Cytox sales and marketing update

...software ito diagnose Alzheimer’s disease by determining amyloid positive patients from blood or archived samples. Cytox...
...customers on a worldwide basis. The array, marketed as the Axiom Dementia Research Array, includes Cytox’s...
...Fisher Scientific Inc. (NYSE:TMO, Waltham, Mass.) (see BioCentury, Aug. 24, 2015 & April 4, 2016). Cytox Ltd....
BioCentury | Aug 24, 2015
Company News

Affymetrix, Cytox deal

...The collaboration will combine Affymetrix’s Axiom genotyping platform with a customized genetic variation panel from Cytox...
...for manufacturing. The companies did not disclose financial details. Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif. Cytox Ltd....
BioCentury | Apr 7, 2014
Financial News

Cytox completes venture financing

Cytox Ltd. , Birmingham, U.K. Business: Neurology Date completed: 4/3/14 Type: Venture financing Raised: £1.5 million ($2.5 million) Investors: Spark Northwest Fund for Biomedical; Wren Capital; Rainbow Seed Fund; Private investors; Seneca Partners WIR Staff...
BioCentury | Mar 20, 2014
Tools & Techniques

Plasma lipids: harbingers of AD?

...Phase I to Phase II testing to treat AD. According to Richard Pither, CEO of Cytox Ltd....
..."This panel of markers could help get those compounds into the right patients," he said. Cytox...
...Chicago, Ill. Alzheimer's Drug Discovery Foundation , New York, N.Y. Butler Hospital , Providence, R.I. Cytox Ltd....
BioCentury | Mar 17, 2014
Clinical News

MTOR Research Assay: Clinical trial started

...who have been diagnosed with probable AD, fronto-temporal lobe dementia or dementia with Lewy bodies. Cytox Ltd....
BioCentury | Mar 17, 2014
Clinical News

MTOR Research Assay: Clinical trial started

...company's mTOR Research Assay to evaluate 120 samples from patients with mild cognitive impairment (MCI). Cytox Ltd....
BioCentury | Mar 21, 2011
Finance

Eyes and ears

...company MediQuest Therapeutics Inc. ; cell therapy company MaxCyte Inc. ; and Alzheimer's disease company Cytox...
BioCentury | Nov 22, 2010
Company News

Cytox board of directors update

Cytox Ltd. , Birmingham, U.K. Business: Neurology Appointed: David Evans as chairman, formerly chairman at DxS Ltd. , now part of Qiagen N.V. ; he replaces Jim Hawkins, who is stepping down WIR Staff...
Items per page:
1 - 10 of 16
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...many venture investors to walk away from the space (see “Money Troubles”). One exception is Cytox Ltd....
...The assay screens for 130,000 SNPs, including about 30,000 associated with mTOR signaling in AD. Cytox...
...are correlated with amyloid deposition and other pathways implicated in AD in genome-wide association studies. Cytox...
BioCentury | Aug 8, 2016
Company News

Cytox sales and marketing update

...software ito diagnose Alzheimer’s disease by determining amyloid positive patients from blood or archived samples. Cytox...
...customers on a worldwide basis. The array, marketed as the Axiom Dementia Research Array, includes Cytox’s...
...Fisher Scientific Inc. (NYSE:TMO, Waltham, Mass.) (see BioCentury, Aug. 24, 2015 & April 4, 2016). Cytox Ltd....
BioCentury | Aug 24, 2015
Company News

Affymetrix, Cytox deal

...The collaboration will combine Affymetrix’s Axiom genotyping platform with a customized genetic variation panel from Cytox...
...for manufacturing. The companies did not disclose financial details. Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif. Cytox Ltd....
BioCentury | Apr 7, 2014
Financial News

Cytox completes venture financing

Cytox Ltd. , Birmingham, U.K. Business: Neurology Date completed: 4/3/14 Type: Venture financing Raised: £1.5 million ($2.5 million) Investors: Spark Northwest Fund for Biomedical; Wren Capital; Rainbow Seed Fund; Private investors; Seneca Partners WIR Staff...
BioCentury | Mar 20, 2014
Tools & Techniques

Plasma lipids: harbingers of AD?

...Phase I to Phase II testing to treat AD. According to Richard Pither, CEO of Cytox Ltd....
..."This panel of markers could help get those compounds into the right patients," he said. Cytox...
...Chicago, Ill. Alzheimer's Drug Discovery Foundation , New York, N.Y. Butler Hospital , Providence, R.I. Cytox Ltd....
BioCentury | Mar 17, 2014
Clinical News

MTOR Research Assay: Clinical trial started

...who have been diagnosed with probable AD, fronto-temporal lobe dementia or dementia with Lewy bodies. Cytox Ltd....
BioCentury | Mar 17, 2014
Clinical News

MTOR Research Assay: Clinical trial started

...company's mTOR Research Assay to evaluate 120 samples from patients with mild cognitive impairment (MCI). Cytox Ltd....
BioCentury | Mar 21, 2011
Finance

Eyes and ears

...company MediQuest Therapeutics Inc. ; cell therapy company MaxCyte Inc. ; and Alzheimer's disease company Cytox...
BioCentury | Nov 22, 2010
Company News

Cytox board of directors update

Cytox Ltd. , Birmingham, U.K. Business: Neurology Appointed: David Evans as chairman, formerly chairman at DxS Ltd. , now part of Qiagen N.V. ; he replaces Jim Hawkins, who is stepping down WIR Staff...
Items per page:
1 - 10 of 16